Ongoing In Vivo Immunoglobulin Class Switch DNA Recombination in Chronic Lymphocytic Leukemia B Cells

Andrea Cerutti, Hong Zan, Edmund C. Kim, Shefali Shah, Elaine J. Schattner, András Schaffer and Paolo Casali

*J Immunol* 2002; 169:6594-6603; doi: 10.4049/jimmunol.169.11.6594
http://www.jimmunol.org/content/169/11/6594

**References**  This article cites 77 articles, 48 of which you can access for free at: http://www.jimmunol.org/content/169/11/6594.full#ref-list-1

**Subscription**  Information about subscribing to *The Journal of Immunology* is online at: http://jimmunol.org/subscription

**Permissions**  Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html

**Email Alerts**  Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts
Ongoing In Vivo Immunoglobulin Class Switch DNA Recombination in Chronic Lymphocytic Leukemia B Cells

Andrea Cerutti,* Hong Zan,* Edmund C. Kim,† Shefali Shah,* Elaine J. Schattner,‡ András Schaffer,*† and Paolo Casali*†

Chronic lymphocytic leukemia (CLL) results from the expansion of malignant CD5+ B cells that usually express IgD and IgM. These leukemic cells can give rise to in vivo to clonally related IgG or IgA elements. The requirements and modalities of this process remain elusive. Here we show that leukemic B cells from 14 of 20 CLLs contain the hallmarks of ongoing Ig class switch DNA recombination (CSR), including extrachromosomal switch circular DNAs and circle transcripts generated by direct $S_{\mu} \rightarrow S_{\gamma}$, $S_{\mu} \rightarrow S_{\alpha}$, and $S_{\mu} \rightarrow S_{\epsilon}$ as well as sequential $S_{\gamma} \rightarrow S_{\alpha}$ and $S_{\gamma} \rightarrow S_{\epsilon}$ CSR. Similar CLL B cells express transcripts for activation-induced cytidine deaminase, a critical component of the CSR machinery, and contain germline $I_{H\cdot C_{H}}$ and mature $V_{H\cdot DJ_{H\cdot C_{H}}}$ transcripts encoded by multiple $C_{\gamma}$, $C_{\alpha}$, and $C_{\epsilon}$ genes. Ongoing CSR occurs in only a fraction of the CLL clone, as only small proportions of $CD5^+$CD19+ cells express surface IgG or IgA and lack IgM and IgD. In vivo class-switching CLL B cells down-regulate switch circles and circle transcripts in vitro unless exposed to exogenous CD40 ligand and IL-4. In addition, CLL B cells that do not class switch in vivo activate the CSR machinery and secrete IgG, IgA, or IgE upon in vitro exposure to CD40 ligand and IL-4. These findings indicate that in CLL at least some members of the malignant clone actively differentiate in vivo along a pathway that induces CSR. They also suggest that this process is elicited by external stimuli, including CD40 ligand and IL-4, provided by bystander immune cells. *The Journal of Immunology, 2002, 169: 6594–6603.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked
in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This work was supported by U.S. Public Health Service National Institutes of Health Grant AR47872, a New Investigator Grant from the Leukemia Research Foundation, and a Career Development Award from the S.L.E. Foundation (to A.C.) and by U.S. Public Health Service National Institutes of Health Grants AI45011, AG13910, AR40908, and AI07621 (to P.C.).

2 Address correspondence and reprint requests to Dr. Andrea Cerutti, Weill Medical College of Cornell University, 1300 York Avenue, New York, NY 10021. E-mail address: acerutti@med.cornell.edu

3 Abbreviations used in this paper: CLL, chronic lymphocytic leukemia; AID, activation-induced cytidine deaminase; CD40L, CD40 ligand; CSR, class switch DNA recombination; CT, circle transcript; GC, germinal center; GST-CD40IC, GST intracytoplasmic CD40 fusion protein; ht, human trimeric; IgG, Ig germline transcript; IKK, IkB kinase; S, switch region; SC, switch circle; SSCP, single-stranded conformation polymorphism; TRAF, TNFR-associated factor; $V_{H\cdot D_{H\cdot C_{H}}}$, Ig mature transcript.
to as the circular transcript (CT) (36). Since SCs are rapidly degraded by nuclease, both SCs and CTs constitute specific molecular markers of ongoing CSR (36, 37). The presence of ongoing CSR in CLL B cells remains elusive.

We show here that leukemic B cells from the majority of CLL patients contain SCs as well as CTs deriving from ongoing direct or sequential CSR to \( \gamma \), \( \alpha \), or \( \varepsilon \). These CLL B cells down-regulate CSR in vitro unless exposed to exogenous CD40L and IL-4. In nonactively class-switching CLL B cells, the CD40 and IL-4 receptors are functional and retain the ability to induce CSR. These findings indicate that at least some members of the CLL clone actively differentiate in vivo along a GC-like pathway that includes CSR. This ongoing differentiation may reflect the in vivo exposure of leukemic cells to external stimuli, such as CD40L and IL-4 provided by normal bystander immune cells.

Materials and Methods

Cells

Leukemic cells were isolated from the peripheral blood of 20 untreated CLL patients. The diagnosis of CLL was established according to standard criteria that included the expression of the marker CD5, CD23, and CD20 as well as CD5 and CD20 as negative. The frequency of patients containing SCs as well as CTs deriving from ongoing direct or sequential CSR (36, 37). The presence of ongoing CSR includes CSR. This ongoing differentiation may reflect the in vivo exposure of leukemic cells to external stimuli, such as CD40L and IL-4 provided by normal bystander immune cells.

Genomic PCRs

Genomic DNA was extracted from B cells using the QIAmp DNA Mini kit (Qiagen, Chatsworth, CA) (27). SCs were amplified from 500 ng of genomic DNA using a previously described nested PCR strategy (27). The conditions were denaturation for 1 min at 94°C, annealing for 1 min at 58°C, and extension for 4 min at 72°C for two rounds of 30 cycles. Before each PCR, DNA was denatured for 5 min at 94°C. The identity of PCR products with SCs was confirmed by DNA sequencing. Genomic \( \beta \)-actin was amplified as previously reported (27).

RT-PCRs

Total RNA was isolated from B cells using the RNeasy Total RNA kit (Qiagen). RNA (2 \( \mu \)g) was reverse transcribed using the reverse transcriptase Superscript and a poly(dT) 12,18 primer (Invitrogen, Carlsbad, CA) (27). 1y-C, 1x-C, and 1x-C TEs were RT-PCR amplified for 30 cycles using the reverse primer C\( _A \) (5'-GTTGGCGTGGGTGCTGAC-3') together with the forward primers 1y (5'-GGGCTTCACAGCAACGGG CAGGACA-3'); this primer recognizes 1y1 and 1y2), 1x (5'-CAGCGGC CCTCTTGAGGGAAGCAGC-3'); this primer recognizes both 1x1 and 1x2), and 1e (5'-GACGGGCGACCATCACCCAGCGCATAATGACAGAC-3'); this primer recognizes sequence shared by all \( \gamma \) regions, together with the forward primers 1e (5'-CAGCGGCTTGGTGGGCACACC-3') and 1e (5'-GGGGCGACCATCACCCAGCGCATAATGACAGAC-3'). The conditions were denaturation for 1 min at 94°C, annealing for 1 min at 58°C, and extension for 1 min at 72°C. Before each RT-PCR, cDNAs were denatured for 5 min at 94°C. PCRs were made semiquantitative by performing dilutional analysis so that there was a linear relationship between the amount of cDNA used and the intensity of the PCR product.

Southern blots

PCR products were fractionated onto agarose gels, transferred overnight onto nitrocellulose membranes, and hybridized with specific probes (27). \( \text{Sy-Sy}, \text{Se-Sy}, \text{Se-Sy} \), and \( \text{Se-Sy} \) were hybridized with a probe recognizing the recombinated \( \mu \) region, whereas \( \text{Se-Sy} \) and \( \text{Se-Sy} \) were labeled with a probe recognizing the recombinated \( \gamma \) region. Hybridization products appear smeary on gel electrophoresis, as each switching B cell produces a single copy SC with a unique size. 1y-C, 1x-C, and 1e-C were hybridized with a probe encompassing at 1–250 of the first \( \gamma \) exon. 1x-C and 1e-C were hybridized with a probe encompassing at 1–200 of the first \( \gamma \) exon.

Single-strand conformation polymorphism analysis (SSCP) and DNA sequencing

CLL V\( _D_jD_j \) transcripts were identified by SSCP (41). Briefly, cDNAs were PCR amplified with Taq DNA polymerase (Life Technologies, Gaithersburg, MD) using the cloned cdNA inserted into pCR-Blunt II TOPO vector as template. The internal \( \text{V} \) \( \alpha \) leader sense primer and \( \text{J} \) \( \alpha \) antisense primer were used for V\( _D_jD_j \) analysis. Samples were denatured and immediately loaded onto a pre-cast polyacrylamide gel (GeneGel Excel 12.5/2 Kit; Amersham Pharmacia Biotech, Piscataway, NJ). Fractionated cDNAs were silver stained using a PlusOne DNA Silver Staining Kit (Amersham Pharmacia Biotech). IgV\( _D_jD_j \) transcripts were sequenced as previously reported (41), and sequences were compared with the germine counterpart and with the original CLL IgV\( _D_j \) sequence using MacVector version 5.0 software (International Biotechnologies, New Haven, CT).

Cultures and reagents

CLL B cells were cultured in six-well plastic plates with 5 ml of RPMI 1640 medium supplemented with 10% heat-inactivated FBS (Life Technologies), 2 mM l-glutamine, 100 U/ml of penicillin, and 100 \( \mu \)g/ml of streptomycin. Human trimeric (ht) CD40L (Immunex, Seattle, WA), IL-4, and IL-10 (Schenking-Plough, Kenilworth, NJ) were used at 1 \( \mu \)g/ml, 250 U/ml, and 200 ng/ml, respectively.

Flow cytometry and ELISAs

mAbs to CD5, CD19, CD71 (Beckman Coulter), CD38, CD38 (BD PharMingen, San Diego, CA), IgD, IgM, IgA, and IgG (Southern Biotechnologies, Associates, Birmingham, AL) were conjugated with FITC or PE. CD77 was labeled with an unconjugated mouse mAb (Beckman Coulter) and a PE-conjugated Ab to mouse Igs (BD PharMingen). Cells were acquired using a FACSCalibur analyzer (BD Biosciences, San Jose, CA). Secreted IgM, IgG, IgA, and IgE were detected by standard ELISAs (27).

FIGURE 1. Generation and composition of SCs and CTs. The human IgH chain locus and the molecular events involved in switching from C\( _\alpha \) to C\( _\varepsilon \) are shown schematically. Ovals indicate S regions; rectangles before and after the S regions are Ig exons and C\( _\varepsilon \) gene exons, respectively; \( \text{J} \)\( _{\mu} \) is the IgH chain intronic enhancer; triangles are the 3' regions, together with the molecular events involved in switching from C\( _\alpha \) to C\( _\varepsilon \).

V-shaped lines indicate splicing; arrowheads indicate the positions and directions of the primers used to amplify SCs, CTs, germine transcripts, and mature transcripts.
Pull-down assays, immunoblots, and in vitro kinase assay

After cell lysis (40), total proteins were pulled down with a GST-CD40 intracytoplasmic (GST-CD40IC) fusion protein (from Dr. V. M. Dixit, Genentech, South San Francisco, CA) reacted with glutathione-agarose beads (Sigma, St. Louis, MO). Pulled-down proteins were fractionated on 10% SDS-PAGE and transferred to nitrocellulose membranes. After blocking, membranes were immunoblotted with Abs to TNFR-associated factor-2 (TRAF-2) or TRAF-6 (Santa Cruz Biotechnology, Santa Cruz, CA). Proteins were detected with an enhanced chemiluminescence detection system (Amersham, Little Chalfont, U.K.). To perform solid phase IκBα kinase (IKKα) assays, an IκBα-GST fusion protein (from Dr. M. Karin, University of California, San Diego, CA) was reacted with glutathione-agarose beads and incubated for 15 min with total cell lysates, kinase buffer, and [γ-32P]ATP. Following extensive washes, phosphorylated IκBα was boiled in SDS sample buffer, and eluted proteins were run on a 15% SDS-PAGE. Phosphorylated IκBα was detected by autoradiography.

Electrophoretic mobility shift assays

B cells were cultured for 6 h, and nuclear proteins were extracted using a modified version of Schreiber’s method (30). Double-stranded oligonucleotide probes encompassing the κB1 and STAT-6 binding sites within the germline Cy μ gene promoter were prepared as previously described (30). These probes were labeled with [α-32P]dCTP and [α-32P]dGTP using the Klenow fragment of DNA polymerase I (Roche, Indianapolis, IN). DNA binding reactions and shift assays were performed as previously reported (30).

Results

Normal GC, but not naive and memory B cells, express SCs, CTs, and AID

In healthy subjects, IgD+CD38+ and IgD+CD38− B cells account for ~85 and 15% of peripheral blood B lymphocytes, respectively, and include naive and memory B cells (42). In secondary lymphoid organs, B lymphocytes encompass four distinct populations, including IgD+CD38+ naive B cells, IgD+CD38+ founder GC B cells, IgD+CD38+ GC B cells, and IgD+CD38− memory B cells (7, 43, 44). Previous studies indicate that class switching initiates in GC B cells and is completed in memory B cells (9, 43). To determine the differentiation stage at which ongoing direct and sequential CSR occurs, we evaluated the presence of SCs, CTs, and AID (Fig. 1) in normal peripheral blood CD19+ B cells as well as in tonsillar B cell subsets. Total peripheral blood B cells from four healthy subjects did not contain traces of ongoing direct CSR, including IgD−μ, Se-μ, or Se-μ SCs (Fig. 2A); Iγ-μ, Iα-μ, or Iε-μ CTs; and AID transcripts (Fig. 2B). Similar cells lacked markers of ongoing sequential CSR from Cy to Cε or Cε, including Iγ-σα and Iγ-σε SCs and Iα-ε Cγ and Iε-ε CTs. Similarly, tonsil IgD+CD38− and IgD+CD38+ B cells did not contain SCs, nor did they express CTs or AID transcripts. In contrast, IgD+CD38+ B cells contained Iγ-μ, Se-μ, and Iε-μ SCs and Iγ-μ and Iα-μ CTs as well as AID transcripts. As expected, IgD+CD38− B cells contained Iγ-μ, Se-μ, Se-μ, Iγ-σα, and Iγ-σε SCs; Iγ-μ, Iα-μ, Iε-μ, Iε-ε, and Iε-ε Cγ and CTs; and AID transcripts. These findings indicate that in healthy subjects, ongoing CSR is virtually absent in peripheral blood B cells and segregates within founder GC and GC B cells.

CLL B cells contain SCs and express CTs and AID in vivo

The presence of actively ongoing CSR in CLL remains elusive. We detected SCs in leukemic B cells from 14 of 20 CLLs (70%). Sy-μ
SCs were detected in nine of 20 (45%) CLLs, Sα- Sμ SCs in 13 of 20 CLLs (65%), Sε- Sμ SCs in eight of 20 CLLs (40%), Sα- Sy SCs in seven of 20 CLLs (35%), and Sε- Sy SCs in four of 20 CLLs (20%; Table I). In some CLLs, including CLL E-28, E-137, and E-92, malignant B cells simultaneously expressed Sy-Sμ, Sα-Sμ, Sε-Sμ, Sα-Sγ, and Sε-Sγ SCs. The expression of CTs and AID was analyzed in eight of the 14 CLLs containing SCs as well as in four of the CLLs lacking SCs. The leukemic B cells from the eight cases containing SCs also expressed the corresponding CTs and AID transcripts. In contrast, the leukemic B cells from the four patients who lacked SCs and CTs did not express significant AID (Fig. 3). These results demonstrate that in the majority of CLLs at least some members of the leukemic clone display traces of ongoing direct and sequential CSR.

In vivo class-switching CLL B cells down-regulate SCs and CTs in vitro

In normal B cells, SCs and CTs are extinct a few days after the removal of CSR-inducing stimuli (36). We hypothesized that if CLL B cells undergo CSR in vivo in response to external stimuli, such as CD40L and IL-4, then such leukemic cells should down-regulate CSR once transferred in vitro in the absence of these

### Table I. Distribution of SCs in leukemic B cells

<table>
<thead>
<tr>
<th>CLL Case</th>
<th>Direct CSR</th>
<th>Sequential CSR</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Cμ→Cγ</td>
<td>Cμ→Cε</td>
</tr>
<tr>
<td>E-28</td>
<td>Sγ-Sμ</td>
<td>Sα-Sμ</td>
</tr>
<tr>
<td>E-48</td>
<td>Sγ-Sμ</td>
<td>Sα-Sμ</td>
</tr>
<tr>
<td>E-49</td>
<td>Sα-Sμ</td>
<td>Sε-Sμ</td>
</tr>
<tr>
<td>E-73</td>
<td>Sα-Sμ</td>
<td>Sε-Sμ</td>
</tr>
<tr>
<td>E-60</td>
<td>Sα-Sμ</td>
<td>Sε-Sμ</td>
</tr>
<tr>
<td>E-69</td>
<td>Sα-Sμ</td>
<td>Sε-Sμ</td>
</tr>
<tr>
<td>E-101</td>
<td>Sγ-Sμ</td>
<td>Sα-Sμ</td>
</tr>
<tr>
<td>E-103</td>
<td>Sγ-Sμ</td>
<td>Sα-Sμ</td>
</tr>
<tr>
<td>E-104</td>
<td>Sα-Sμ</td>
<td>Sε-Sμ</td>
</tr>
<tr>
<td>N-123</td>
<td>Sα-Sμ</td>
<td>Sε-Sμ</td>
</tr>
<tr>
<td>N-137</td>
<td>Sγ-Sμ</td>
<td>Sα-Sμ</td>
</tr>
<tr>
<td>N-178</td>
<td>Sγ-Sμ</td>
<td>Sα-Sμ</td>
</tr>
<tr>
<td>N-169</td>
<td>Sγ-Sμ</td>
<td>Sα-Sμ</td>
</tr>
<tr>
<td>N-216</td>
<td>Sα-Sμ</td>
<td>Sε-Sμ</td>
</tr>
<tr>
<td>N-249</td>
<td>Sα-Sμ</td>
<td>Sε-Sμ</td>
</tr>
<tr>
<td>N-261</td>
<td>Sα-Sμ</td>
<td>Sε-Sμ</td>
</tr>
<tr>
<td>E-105</td>
<td>Sγ-Sμ</td>
<td>Sα-Sμ</td>
</tr>
<tr>
<td>E-92</td>
<td>Sγ-Sμ</td>
<td>Sα-Sμ</td>
</tr>
</tbody>
</table>

**FIGURE 3.** Malignant CLL B cells contain SCs and express CTs and AID. Sγ-Sμ, Sα-Sμ, Sε-Sμ, Sα-Sγ, and Sε-Sγ SCs (A); and Iγ-Cμ, Iα-Cμ, Iε-Cμ, Iα-Cγ, and Iε-Cγ CTs and AID (B) were PCR amplified from peripheral blood malignant B cells from 12 CLLs. Two Iγ-Cμ and Iα-Cμ bands represent alternatively spliced transcripts. β-Actin genomic DNA was PCR amplified to control DNA loading. Sγ-Sμ, Sα-Sμ, and Sε-Sμ were hybridized with an Sμ probe; Sα-Sγ and Sε-Sγ were hybridized with a Sy probe; Iγ-Cμ, Iα-Cμ, and Iε-Cμ were hybridized with a Cμ probe; Iα-Cγ and Iε-Cγ were hybridized with a Cγ probe.
In vivo class-switching CLLs display intraclonal phenotypic diversification

In vivo class-switching CLLs display clonally related IgG and IgA

The monoclonality of CLL B cells undergoing in vivo CSR was confirmed by the homogeneous electrophoretic mobility profile of the dsDNA bands of 48 V\textsubscript{H}DJ\textsubscript{H} transcripts after SSCP analysis, as exemplified by CLL E-123 (Fig. 5B). In addition, the nucleotide sequences of V\textsubscript{H}DJ\textsubscript{H}-C\textsubscript{\gamma} -C\textsubscript{\delta}, -C\textsubscript{\gamma}, and -C\textsubscript{\alpha} transcripts were colinear and displayed the same differences as the putative germline template (Fig. 5C). This indicates that in CLL E-123, surface IgG and IgA are clonally related to the IgM and IgD expressed by the dominant population. As recently reported (20), CLLs, including actively class-switching CLL N-105, N-169, N-178, and N-249, can display a variable degree of intraclonal Ig V\textsubscript{H}DJ\textsubscript{H} gene diversity. This is shown by the inconsistent mobility profile of some single-strand Ig V\textsubscript{H}DJ\textsubscript{H} transcripts. Consistent with this, the mobility profile of single-strand V\textsubscript{H}DJ\textsubscript{H} transcripts 17 and 48 from CLL E-123 was different from that of the dominant population (Fig. 5B). DNA sequencing showed that these differences reflect the presence of two intraclonal V\textsubscript{H}DJ\textsubscript{H} gene point mutations (not shown). In agreement with previous reports documenting the independence of CSR and Ig V(D)J gene somatic hypermutation in both normal and neoplastic CD\textsuperscript{5}+ B cells (24, 26, 47), intraclonal Ig V\textsubscript{H}DJ\textsubscript{H} diversification did not correlate with ongoing class switching, as nonactively class-switching CLL E-69, E-73, E-130, and N-261 displayed intraclonal diversification, but not CSR (20) (data not shown).

In vivo class-switching CLL B cells express multiple germline and mature Ig transcripts

The transcriptional status of the Ig H chain locus was analyzed in well-characterized B cell subsets and CLL B cells. IgD\textsuperscript{+}CD38\textsuperscript{+}naive B cells lacked germline I\textsubscript{\gamma}1-C\textsubscript{\gamma}1 transcripts and expressed only V\textsubscript{H}DJ\textsubscript{H}-C\textsubscript{\gamma1-C\textsubscript{\gamma}1} mature transcripts (Fig. 6). Compared with these cells, normal IgD\textsuperscript{+}CD38\textsuperscript{+} founder GC B cells were up-regulated germline I\textsubscript{\gamma}1-C\textsubscript{\gamma}1, I\textsubscript{\gamma}2-C\textsubscript{\gamma}2, I\textsubscript{\gamma}3-C\textsubscript{\gamma}3, I\textsubscript{\alpha}1-C\textsubscript{\alpha}1, and I\textsubscript{\alpha}2-C\textsubscript{\alpha}2 transcripts and expressed mature V\textsubscript{H}DJ\textsubscript{H}-C\textsubscript{\gamma1-C\textsubscript{\gamma}1}, -C\textsubscript{\gamma2}, -C\textsubscript{\alpha1}, and -C\textsubscript{\alpha2} transcripts. IgD\textsuperscript{+}CD38\textsuperscript{+} GC B cells further up-regulated all downstream germline transcripts, including I\textsubscript{\gamma}4-C\textsubscript{\gamma}4 and I\textsubscript{\epsilon}-C\textsubscript{\epsilon}, as well as all downstream mature transcripts, including V\textsubscript{H}DJ\textsubscript{H}-C\textsubscript{\gamma4} and C\textsubscript{\epsilon}. Finally, IgD\textsuperscript{+}CD38\textsuperscript{+} memory B cells contained all downstream mature transcripts, but only weakly germline I\textsubscript{\gamma}1-C\textsubscript{\gamma}1, I\textsubscript{\gamma}2-C\textsubscript{\gamma}2, and I\textsubscript{\gamma}3-C\textsubscript{\gamma}3 transcripts.

Malignant B cells from actively class-switching CLLs strongly expressed germline and mature transcripts, with C\textsubscript{\gamma}1, C\textsubscript{\gamma}2, C\textsubscript{\gamma}3, and C\textsubscript{\alpha1} being the most frequently targeted downstream C\textsubscript{\gamma}1 genes. Some of these CLLs, including CLL E-137, expressed all downstream germline and mature transcripts (Fig. 6). Although expressing multiple downstream mature transcripts, including V\textsubscript{H}DJ\textsubscript{H}-C\textsubscript{\gamma1-C\textsubscript{\gamma}1}, C\textsubscript{\gamma}2, C\textsubscript{\gamma}3, and C\textsubscript{\alpha1}, the malignant B cells from nonactively switching CLLs weakly expressed germline I\textsubscript{\gamma}1-C\textsubscript{\gamma}1 transcripts. For instance, CLL E-69 B cells weakly expressed germline I\textsubscript{\gamma}1-C\textsubscript{\gamma}1 and I\textsubscript{\gamma}2-C\textsubscript{\gamma}2 transcripts in addition to producing V\textsubscript{H}DJ\textsubscript{H}-C\textsubscript{\gamma1-C\textsubscript{\gamma}1}, -C\textsubscript{\gamma}, -C\textsubscript{\gamma1}, and -C\textsubscript{\alpha1} mature transcripts. These findings indicate that, like nonmalignant GC B cells, actively class-switching B cells...
cells can express germline and mature Ig transcripts derived from multiple downstream C\textsubscript{\gamma}, C\textsubscript{a}, and C\textsubscript{e} genes.

**CLL B cells that do not class switch in vivo undergo CSR upon in vitro exposure to CD40L and IL-4**

Some CLLs may not class switch in vivo because the transforming event may have altered the physiological CSR-inducing signaling pathway. In normal B cells, CD40 engagement elicits the recruitment of activated TRAF adapter proteins to the CD40 cytoplasmic tail (48). By activating downstream kinases, including IKK, the CD40-TRAF complex induces nuclear translocation of NF-\textgamma\beta (49), which, together with IL-4R-induced STAT-6, activates the I\textgamma\textsubscript{H} promoter and induces I\textgamma\textsubscript{H}-C\textsubscript{H} germline transcription and, eventually, CSR (30).

Malignant B cells from non-class-switching CLLs, including CLL E-69, up-regulated the binding of TRAF-2 and TRAF-6 to a construct encompassing the CD40 cytoplasmic tail and enhanced the activity of IKK\alpha upon exposure to htCD40L alone or with IL-4 (Fig. 7A). Under similar conditions, CLL E-69 B cells up-regulated the binding of NF-\kappaB to a DNA sequence encompassing the CD40-responsive element of the C\gamma3 gene promoter (30). In the presence of htCD40L and/or IL-4, CLL E-69 B cells induced the binding of STAT-6 to a DNA sequence encompassing the IL-4-responsive element of the C\gamma3 gene promoter (30). Similar results were obtained with CLL E-60, E-73, and N-105 (not shown). Thus, both CD40 and IL-4 receptors are functional in CLL B cells that do not class switch in vivo.

We also evaluated whether malignant B cells undergo CSR upon exposure to CD40L and IL-4. Compared with unstimulated CLL E-69 B cells, htCD40L- and IL-4-stimulated CLL E-69 B cells up-regulated 1y1-C\gamma1, 1y2-C\gamma2, 1y3-C\gamma3, 1x1-C\alpha1, 1x2-C\alpha2, and 1x-Ce germline transcripts as well as V\gamma\textsubscript{H}DJ\textsubscript{H}-C\textgamma\textsubscript{H} and Ce mature transcripts (Fig. 7B). Similarly activated CLL E-69 B cells induced also AID as well as S\gamma-S\mu, S\alpha-S\mu, and S\gamma-S\mu SCs (Fig. 7, C and D). Interestingly, malignant B cells from CLLs with ongoing switching to C\gamma3, including CLL E-101 and E-123, underwent sequential switching to C\gamma1 and/or Ce upon exposure to htCD40L and IL-4 (not shown). Finally, htCD40L and IL-4-stimulated CLL E-69 B cells induced IgM, IgG, IgA and IgE secretion, which was further enhanced by IL-10 (Fig. 7E). Thus, nonactively class-switching CLL B cells undergo CSR and Ab secretion upon exposure to external physiological stimuli, including CD40L, IL-4, and IL-10.
FIGURE 6. The transcriptional status of the Ig H chain locus in actively class-switching malignant CLL B cells is similar to that of nonmalignant GC B cells. 1y1-Cy1 (603 bp), 1y2-Cy2 (597 bp), 1y3-Cy3 (670 bp), 1y4-Cy4 (411 bp), Ia1-Ce1 (1194 bp), Ia2-Ce2 (1181 bp), Ie-Ce (409 bp), \( V_{\mu} D_{\mu} C_{\mu} \) (~150 bp), \( V_{\mu} D_{\mu} C_{\mu} \) (~350 bp), \( V_{\mu} D_{\mu} C_{\mu} \) (~415 bp), \( V_{\mu} D_{\mu} C_{\mu} \) (~415 bp), \( V_{\mu} D_{\mu} C_{\mu} \) (~415 bp), \( V_{\mu} D_{\mu} C_{\mu} \) (~415 bp), \( V_{\mu} D_{\mu} C_{\mu} \) (~900 bp), \( V_{\mu} D_{\mu} C_{\mu} \) (~890 bp), and \( V_{\mu} D_{\mu} C_{\mu} \) (~380 bp) were PCRamplified from normal IgD\(^+\)CD38\(^+\) naive B cells, IgD\(^+\)CD38\(^+\) founder GC B cells, IgD\(^+\)CD38\(^+\) memory B cells, and an as yet elusive Ag(s) (20, 53, 59), the GC milieu within the secondary follicle would constitute an ideal microenvironment to foster Ig CSR, plasmacytoid differentiation as well as bcl-6 and V(D)J gene somatic hypermutation (12, 19, 20) in at least some members of the leukemic clone. In addition to actively diversifying their Ig C\(_H\) gene repertoire through CSR, some CLLs intraclonally diversify their surface phenotype. As exemplified by case CLL E-123, this in vivo differentiation process can give rise to CLL fractions that express the GC B cell markers CD38 and CD77, but lack (not shown) the naive B cell markers CD44 and IgD. These GC-like CLL B cells might include the morphologically atypical elements, such as immunoblastic and Hodgkin/Reed-Sternberg-like cells, which can be found in a background of otherwise typical small round elements within the pseudofollicles of certain CLLs (60, 61). Similar to the CD38\(^+\)CD77\(^+\) GC-like cells shown in this study, atypical CLL B cells are clonally related to the dominant CLL population and express GC-like phenotypic and genotypic traits (60, 61). As shown by others (51), we found that transcripts for the GC B cell marker Bcl-6 as well as the Bcl-6 protein were consistently expressed by CLLs with significant CD38\(^+\)CD77\(^+\) GC-like cells, although at lower levels than in GC B cells (not shown). This might reflect the attempt of some members of the CLL clone to progress along a GC differentiation pathway that includes CSR. It is tempting to speculate that in the presence of additional leukemogenic events, including EBV infection, atypical GC-like CLL B cells become the precursors of a second lymphoid neoplasia clonally related to the original CLL (21, 60, 61).

Discussion

The CLL phenotype has been intensively investigated, and new evidence indicates that CLL B cells display a gene signature similar to that of memory B cells (17, 18, 42, 50, 51). It remains unclear whether CLLs further diversify their phenotype in response to environmental stimuli. We show here that in the majority of CLLs at least some members of the malignant clone display ongoing direct and sequential CSR to Cy, Ca, and/or Ce genes in vivo. These cells turn off the CSR machinery in vitro, but reactivate upon exposure to exogenous CD40L and IL-4. Our findings indicate that IgM\(^+\)IgD\(^+\) CLLs are not developmentally static, but actively differentiate in vivo along a maturation pathway that includes direct and sequential CSR to multiple downstream C\(_H\) genes. This differentiation process may be elicited by external stimuli as provided by bystander immune cells.

Previous reports show that IgM\(^+\) CLLs can give rise in vivo to class-switched elements expressing clonally related IgG or IgA (12, 21–26). However, these studies do not clarify whether class switching occurs at a given time point during the evolution of the neoplastic clone or, rather, represents a dynamic process. By showing that freshly isolated CLL B cells contain SCs, CTs, as well as multiple downstream germline I\(_H\)-C\(_H\) and mature V\(_H\) D\(_H\) J\(_H\)-C\(_H\) transcripts, our results demonstrate that Ig class switching stems from the continuous in vivo stimulation of the leukemic CSR machinery. They also suggest that CSR occurs in some, but not all, members of the CLL clone, as only discrete neoplastic fractions express IgG or IgA, but lack IgM and IgD. This intraclonal phenotypic diversification presumably reflects the heterogeneous accessibility of the different components of the neoplastic clone to CSR-inducing stimuli. Alternatively, only some elements of a given CLL clone might be competent to respond to these CSR-inducing stimuli.

Ongoing CSR does not imply that the CLL clone derives from a normal GC B cell precursor. Rather, it suggests that some members of the clone differentiate in response to either intrinsic or environmental stimuli. Our findings support this latter interpretation, as CLL B cells that actively class switch in vivo turn off the CSR machinery once transferred in vitro unless exposed to CD40L and IL-4. The possible relevance of external CD40L and IL-4 in the evolution of the CLL clone is supported by studies showing that freshly isolated CLL B cells express increased nuclear NF-κB (52), display a phenotype similar to that of recently activated B cells (18, 53), and are enriched in genes related to the IL-4R signaling pathway (17). Furthermore, CLL B cells proliferate, secrete lgs, and are rescued from apoptosis upon in vivo exposure to CD40L and/or IL-4 (25, 52, 54–56).

CLL B cells might be exposed to CD40L and IL-4 in the context of leukemic pseudofollicles, also known as proliferation centers, which have been recently shown to be extensively infiltrated by activated CD4\(^+\) T cells. These T cells would colonize the pseudofollicle by navigating through a chemoattractant gradient established by CLL B cell-derived chemokines, including CCL22 (57). Alternatively, CLL B cells could be activated by CD40L and IL-4 as they transit through the GC of a reactive secondary lymphoid follicle. Consistent with this, certain CLLs are characterized by an interfollicular proliferation pattern in which the neoplastic B cells surround and sometimes colonize large reactive lymphoid follicles (58). By favoring the interaction of CLL B cells with CD4\(^+\) T cells and an as yet elusive Ag(s) (20, 53, 59), the GC milieu within the secondary follicle would constitute an ideal microenvironment to foster Ig CSR, plasmacytoid differentiation as well as bcl-6 and V(D)J gene somatic hypermutation (12, 19, 20) in at least some members of the leukemic clone.
The possibility remains that the members of the CLL clone that class switch in vivo follow a maturation pathway distinct from that of a classical GC B cell. This view is supported by studies showing that B cells, including CD5⁺/H11001 B cells and marginal zone B cells, undergo CSR and somatic hypermutation outside the GC without the help of CD4⁺/H11001 T cells and in a CD40L-independent fashion (62–65). Regardless of the T cell-dependent or T cell-independent nature of the CSR-inducing stimuli, our findings strongly indicate that some members of the CLL clone actively differentiate in vivo in response to external stimuli. Consistent with reports showing accumulation of monoclonal Igs in the plasma and urine of some patients (21, 66), some of the CLLs with ongoing CSR include elements resembling typical plasma cells. In addition to expressing CD38 and CD138 (syndecan-1), these cells contain large amounts of cytoplasmic Igs as well as transcripts for Blimp-1 (not shown), a transcription factor involved in the progression of activated B cells to plasma cells (67, 68). Our findings extend previous reports suggesting that some CLL B cells retain the ability to undergo plasmacytoid differentiation in response to exogenous stimuli including Ag and cytokines (69). In the presence of additional transforming events, these plasmacytoid CLL B cells might give rise to a multiple myeloma clonally related to the original CLL (70).

The lack of ongoing CSR in certain CLLs, such as case CLL E-69, could derive from their unresponsiveness to exogenous stimuli due to genetic alterations caused by the leukemogenic event. This hypothesis appears unlikely, as neoplastic B cells from CLL E-69 and other nonactively class-switching CLLs activate TRAFs and IKKα and induce nuclear translocation of NF-κB and STAT-6 upon in vitro exposure to CD40L and IL-4. Together with IL-10, these stimuli induce germline CH₃ transcription, CSR, and IgG, IgA, and IgE production in CLL B cells. An alternative explanation for the absence of ongoing CSR in certain CLLs might be that external CSR-inducing stimuli, namely CD40L, are not accessible to the leukemic cells. Consistent with this, in some patients CD4⁺ T cells express less CD40L as a result of an inhibitory effect mediated by the malignant B cells (39, 71).

In agreement with reports indicating that IgA is the most represented secondary isotype in normal and leukemic CD5⁺ B cells (24, 26, 72), we found that CSR from C₅μ to Cα occurs more frequently than CSR from C₅α to Cγ or Cε in CLL B cells. This could be related to the increased propensity of CLL B cells to produce and respond to TGF-β (17, 73), a cytokine inducing switching to IgA (27, 29). A smaller, but significant, proportion of CLLs actively undergo direct CSR from C₅μ to Cε or (not shown)
Cyt4 as well as sequential CSR from Cyt to Cε. Given the well-known dependence of both IgE and IgG4 production on IL-4, our findings suggest that in some cases, the leukemic clone is chronically exposed to an IL-4-rich environment (27). This interpretation would be consistent with recent studies showing that in CLL patients, T cells produce more IL-4 (39) and malignant B cells express more IL-4R but less suppressor of cytokine signaling 1, an inhibitor of IL-4 receptor signaling (17).

The ongoing CSR in some leukemic B cells contrasts with the severe impairment of IgG and IgA production by nonmalignant B cells (74). This acquired immune deficiency leads to recurrent infections and is thought to be secondary to the abnormal expansion of T cells with CSR inhibitory activity, including CD8+CD28+CD30+ and CD4+CD28+CD30- T cells (39, 40). These latter constitutively express CD25 and might include CD4+CD25+ T cells, a regulatory subset that inhibits both humoral and cellular immune responses (75).

Several mechanisms would account for the inhibition of CSR in normal rather than in leukemic B cells. By selectively attracting CD4+CD40L- T cells through chemokines (57), CLL B cells might sequester Th cells and generate an imbalance between helper and suppressor T cells within the leukemic and normal B cell compartments. In addition, by progressively outnumbering nonmalignant B cells in secondary lymphoid follicles, CLL B cells might become the only elements effectively exposed to external CSR-inducing stimuli.

Our findings have important biological implications, as the same stimuli that actively induce CSR, such as CD40L and IL-4, may enhance the in vivo accumulation of some elements of the CLL clone (52, 54, 56). Furthermore, ongoing CSR might introduce genomic instability. This together with EBV infection, immunosuppression, and chemotherapy-induced DNA damage could play an important role in the emergence of a new neoplasia clonally related to CLL, such as large cell non-Hodgkin lymphoma, in Richter’s syndrome, Hodgkin’s lymphoma, or multiple myeloma (61, 70, 76–78). Thus, markers of ongoing CSR and plasmacytoid differentiation could be combined with other parameters, including Ig V/DJ gene somatic hypermutation, to better define CLL prognostic subgroups and, perhaps, identify patients at risk of developing a secondary lymphoid tumor.

Acknowledgments

We thank Dr. Nicholas Chiorazzi (North Shore-Long Island Jewish Research Institute, Manhasset, NY) for providing us with CLL N-105, N-169, N-178, N-216, N-249, and N-261; Kathleen S. Picha (Immunex, Seattle, WA) for hIcd40L; Dr. Vishva M. Dixit (Genentech, San Francisco, CA) for CD40IC-GST; and Dr. M. Karin (University of California, San Diego, CA) for IκBα-GST.

References


Downloaded from http://jimmunol.org/ by guest on April 6, 2017


